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Abstract
Autoimmune polyendocrinopathy-candidiasis-ectodermal-dystrophy (APECED) is a rare primary immunodeficiency
disorder typically caused by homozygous AIRE gene mutation. It is characterized by the association of multiple
autoimmune diseases, with a classical triad including chronic mucocutaneous candidiasis, hypoparathyroidism and
adrenocortical failure. Its clinical spectrum has significantly enlarged in the last years with the apparence of new
entities. One of these novel manifestations is the chronic inflammatory demyelinating polineuropathy (CIDP),
that is characterized by involvement of peripheral nervous system, with nerve demyelination, progressive muscular
weakness of both arms and legs and sensory loss. The identification of myelin protein zero as an important
autoantigen (Ag) in CIDP may suggest the development of Ag-based therapies, such as Ag-specific DNA
vaccination or infusion of Ag-coupled cells.
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Background
Autoimmune polyendocrinopathy-candidiasis-ectodermal-
dystrophy (APECED) is a rare primary immunodeficiency
disorder, which is typically caused by homozygous AIRE
gene mutations [1, 2]. It is a T-cell mediated disease with
increased frequencies of CD8+ effectors and reduction of
FoxP3 + T regulatory cells. In addition, APECED patients
show a significant alteration of the B-cell phenotype and a
dysregulation of the B-cell function involving peripheral in-
nate immune mechanisms, particularly those with longer
disease duration [3].
APECED is characterized by the association of multiple
autoimmune diseases, with a classical triad including
chronic mucocutaneous candidiasis, hypoparathyroidism
and adrenocortical failure. Its clinical spectrum has signifi-
cantly enlarged in the last years [4]. In fact, besides the
classical triad, many other endocrine and non-endocrine
autoimmune manifestations, several of which are associ-
ated with significant morbidity or mortality, may occur in
this condition and vary significantly, even inside the same
families and in children with the same AIRE mutations
[5–7]. One of these novel diseases, i.e., the chronic inflam-
matory demyelinating polineuropathy (CIDP), is charac-
terized by an involvement of peripheral nervous system
with nerve demyelination, progressive muscular weakness
of both arms and legs and sensory loss [7].
The aims of this review are: 1) to highlight the mo-
lecular aspects of CIDP in mice and humans; 2) to re-
port the most recent views on its pathogenesis and 3) to
alert pediatricians to the unusual neurological signs of
the disease that may suggest CIDP diagnosis in children.
Mechanisms of Aire action
Aire promotes T cell tolerance to self-antigens by upreg-
ulating the ectopic expression of a wide array of tissue-
specific self-antigens in medullary thymic epithelial cells
(mTECs) within the thymus [8]. Upregulation of self-
antigens in mTECs promotes the deletion of developing
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T cells that recognize these self-antigens with high affin-
ity (Fig. 1a). In patients and mice with mutations in
AIRE, loss of Aire function results in decreased expres-
sion of tissue-specific self-antigens by mTECs and de-
fective negative selection of self-reactive T cells (Fig. 1b)
[9]. Escape of these self-reactive T cells into the periph-
ery predisposes to the development of autoimmunity
against multiple organs.
In addition to its role in the negative selection of ef-
fector T cells, Aire has been implicated also in other
functions, which may promote self-tolerance. For ex-
ample, Aire has been postilated to play a role in antigen
presentation within the thymus [9] and to affect the fre-
quency and function of regulatory T cells (Tregs), which
are T cell subsets with immunosuppressive function.
Thus, Aire may prevent autoimmunity by affecting a
number of immunoregulatory mechanisms.
Since the translated Aire protein is involved in the
transcriptional regulation of the expression of organ-
specific antigens within the thymus, the fundamental
pathogenetic mechanism, in APECED patients, appears
to be T cell mediated [10].
NOD mice heterozygous for the Aire G228W mutation
develop spontaneous autoimmune peripheral
polyneuropathy
A link between Aire deficiency and the development of
autoimmune peripheral neuropathy was made in mice har-
boring the AIRE G228W mutation on the autoimmune-
prone non-obese diabetic (NOD) background. The AIRE
G228W point mutation was originally described in an
Italian kindred with Mendelian inheritance of autoimmunity
and differs from most AIRE mutations in its dominant in-
heritance pattern and distinct pattern of autoimmunity.
To study the effects of this mutation on Aire function, we
engineered knockin mice with the G228W mutation tar-
geted by homologous recombination to the AIRE locus
[11]. Similar to patients with one copy of this mutation,
heterozygous mice (AireGW/+ mice) develop spontaneous
autoimmunity in a pattern distinct from Aireo/o mice.
AireGW/+ mice have partial loss of Aire function in that
mTECs retain approximately 10% of normal levels of
tissue-specific self-antigen expression . This residual anti-
gen expression appears to be sufficient to protect from
certain autoimmune diseases that develop in Aireo/o mice,
including those associated with early lethality on the NOD
background. Survival after the first months may allow de-
velopment of autoimmune manifestations with later onset,
including spontaneous autoimmune peripheral polyneur-
opathy (SAPP).
Of note, the dominant AIRE G305S mutation has also
been associated with the development of neuropathy in
a patient cohort [12]. It is important to underline, how-
ever, that patients with two copies of AIRE mutations
have also been noted to develop neuropathy. Thus, the
development of autoimmune peripheral neuropathy does
not appear to be specific to dominant AIRE mutations
but can occur in patients who have either one dominant
AIRE mutation or two copies of AIRE mutations.
SAPP in NOD.AireGW/+ mice shares multiple features with
CIDP in humans
By 20 weeks of age, approximately 80% of female AireGW/+
mice on the NOD background (NOD.AireGW/+ mice)
Fig. 1 a and b Aire promotes expression of self-antigens in mTECs and deletion of self-reactive T cells within the thymus. a In a normal thymus,
Autoimmune Regulator (Aire) upregulates expression of a large number of tissue-specific self-antigens (Self-Ag) within medullary thymic epithelial
cells (mTECs). Developing T cells which recognize these self-antigens with high affinity are eliminated to prevent these T cells from causing
autoimmunity. b In Aire deficient individuals, lack of Aire expression within mTECs results in decreased expression of tissue-specific self-antigens
in mTECs. Lack of presentation of these self-antigens to self-reactive T cells allows escape of these self-reactive T cells from clonal deletion. Release
of self-reactive T cells into the periphery promotes autoimmunity
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develop spontaneous neuropathy [11, 13] that is not seen
in wildtype (NOD.WT) littermates. Affected mice display
bilateral weakness of the hind limbs that may subse-
quently progresses to severe paralysis of all limbs. This
neuropathy is associated with immune cell infiltration in
NOD.AireGW/+ sciatic nerves, but not in brain or spinal
cord.
In order to demonstrate the importance of immune
cells in the pathogenesis of this neuropathy, we
transferred spleen and lymph node cells from neuro-
pathic NOD.AireGW/+ mice into immunodeficient NOD
Prkdcscid/scid (NOD.scid) mice. All recipients developed
neuropathy by 7 weeks, suggesting that NOD.AireGW/+
immune cells are pathogenic [13]. Furthermore, recipi-
ents of purified CD4+ T cells also developed neuropathy
that was accompanied by immune cell infiltration of
sciatic nerves [12], suggesting that CD4+ T cells are
sufficient to transfer SAPP.
SAPP in NOD.AireGW/+ mice shares a number of features
with CIDP. First, CD4+ T cells and F4/80+ macrophages
are abundant immune cell types in CIDP patient nerve bi-
opsies. Similarly, CD4+ T cells and F4/80+ macrophages
are also prevalent in the immune infiltrates of
NOD.AireGW/+ sciatic nerves [13]. Second, CD4+ helper T
cells in CIDP patients are skewed toward the production
of interferon (IFN) gamma. Similarly, approximately 40%
of CD4+ helper T cells in the sciatic nerve infiltrates of
neuropathic NOD.AireGW/+ produce IFN gamma after in
vitro stimulation and less than 1% produce IL-17 or
IL-4 [12]. Third, increased expression of the chemokine
CXCL10 (IP-10) in sural nerve biopsies is associated with
CIDP. In neuropathic NOD.AireGW/+ mice, CXCL10 ex-
pression is also increased in the sciatic nerves. Finally, de-
myelination is a hallmark of CIDP, and extensive
demyelination is characteristic of sciatic nerves from
neuropathic NOD.AireGW/+ mice [13].
Thus, SAPP in this mouse model recapitulates a num-
ber of features of human CIDP.
Defective central tolerance to P0 underlies the immune
tolerance defect in NOD.AireGW/+ mice
A key question in autoimmune disease is the identity of
inciting antigens. This question has been particularly
difficult to address in CIDP because only a minority of
patient sera samples contain PNS antigen-specific auto-
antibodies. Aire deficiency, on the other hand, has been
associated with autoantibody production against mul-
tiple organs in both mice and humans [7]. We therefore
utilized NOD.AireGW/+ mice as a strategy to identify po-
tential relevant peripheral nerve antigens important in
SAPP [13]. Using autoantibodies present in the sera of
neuropathic NOD.AireGW/+ mice, we isolated an antigen
that appeared to be recognized by all PNS-reactive serum
specimens from NOD.AireGW/+ mice. This antigen was
identified by mass spectrometry to be Myelin Protein zero
(P0), a 28 kD protein which compromises the majority of
peripheral nerve myelin.
P0 is a known autoantigen in PNS autoimmunity in vari-
ous other settings. Although autoantibodies against PNS
antigens occurs in only a minority of CIDP patients, the
most frequent autoantibody specificity is against P0. In
mice other animals, immunization with P0 is sufficient to
provoke Experimental Autoimmune Neuropathy (EAN),
an induced model of autoimmune peripheral neuropathy
that has been widely used to study mechanisms of disease.
Finally, P0 has been identified as an important target anti-
gen in spontaneous PNS autoimmunity which develops in
NOD mice deficient for the costimulatory molecule B7-2,
and NOD mice engineered to express T cells with specifi-
city against P0 develop early onset, fulminant neuropathy.
Based on our working model of Aire action (Fig. 1),
we hypothesized that P0 is also expressed within mTECs
and therefore promotes clonal deletion of P0 specific T
cells developing within the thymus. Furthermore, we hy-
pothesized that thymus expression of P0 would be under
the control of Aire, so that decreased P0 expression
would be detected in mTECs from Aire deficient mice.
In support of this, P0 expression was indeed detectable
within mTECs and detected at approximately 10% of
wildtype levels in mTECs derived from NOD.AireGW/+
mice [12]. Additionally, as would be expected if lack of
clonal deletion was occurring in Aire-deficient thymus,
increased T cell reactivity to P0 was seen in the spleen
of neuropathic NOD.AireGW/+ mice compared with wild-
type counterparts [12]. Thus, lack of Aire-mediated ex-
pression of P0 in mTECs is associated with increased
immune response to P0 and development of spontan-
eous autoimmunity against the PNS.
P0 is also an autoantigen in APECED patients with CIDP
In people, autoimmune peripheral neuropathy manifests
most commonly as CIDP or Guillan Barre Syndrome.
These diseases occur with a combined prevalence of be-
tween 2 and 8 per 100,000. The pathophysiology of auto-
immune peripheral neuropathy was not well understood,
and, importantly, the pathogenic specific antigen of
autoimmune peripheral neuropathy was not known. In
fact, if there is general agreement that CIDP is an auto-
immune disorder, significant questions remain concern-
ing disease mechanisms and target antigens.
CIDP typically presents as a progressive or relapsing,
symmetrical mainly motor neuropathy with proximal
and distal weakness. The diagnosis of CIDP usually de-
pends upon the electrophysiological studies showing fea-
tures consistent with demielination as prolongation of
distal latency, or reduction in motor conduction velocity,
or prolongation of F wave latency, or absence of F waves,
or partial conduction block, or abnormal temporal
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dispersion, or distal CMAP duration and one other de-
myelinating parameter in one other nerve. Supportive
features for a diagnosis of CIDP include: elevated cere-
brospinal fluid proteins without an increased leukocyte
count; nerve biopsy finding of primary demyelination or
improvement following immunotherapy.
As mentioned previously, two unrelated patients with
mutations in AIRE also spontaneously developed CIDP.
The boys described by our group [7] showed progres-
sive muscular weakness involving both arms and legs,
which was associated with sensory loss and absent ten-
don reflexes.
Electromyograhy (EMG) revealed neurogenic changes
with denervation in the intrinsic muscles of the hands.
Motor and sensory nerve conduction velocities were re-
duced in both ulnar nerves and in the right median
nerve, with signs of chronodispersion.
Sural nerve biopsy, performed in one of these patients
showed moderate demyelination in all nerve fascicles,
patchy CD4-, CD8- and CD68-positive cell infiltration
around two small endoneural blood vessel walls and
moderate subperineural oedema.
No serum autoantibodies against either myelin-
associated glycoprotein or peripheral nerve myelin pro-
teins (GM1 gangliosides and onco-neural antigens-HU),
CV2, amphyphysin) [6]. By radioligand binding assay,
however, both of these patients demonstrated autoanti-
bodies against P0, suggesting that P0 is an important
antigen in both mice and humans deficient in Aire [13].
Current treatments consist primarily of glucocorticoids,
intravenous immunoglobulin (I.V. Ig) and plasmapheresis,
which result in non-specific immunosuppression. Re-
cently, subcutaneous immunoglobulins (SC-Ig) has re-
ceived increasing attention because its efficacy seem to be
similar to I.V.Ig [14–16]. In those patients, neurological
symptoms and electrophysiological tests significantly im-
proved after an initial therapy with I.V.Ig (400 mg/kg per
day for 5 days; therapy regimen was repeated every
3 weeks for two months) followed by one with oral pred-
nisone. After relapse the patient two has started treatment
with SCIg with an increase in autonomy and quality of life
through self treatment. Despite this advance with SCIg,
more specific therapies that target PNS autoimmunity re-
mains an unmet clinical need.
Conclusions
1) MP0 is a target of autoimmunity in APECED
children;
2) therefore, AIRE-mediated autoimmune peripheral
neuropathy should be included among the
components of this syndrome;
3) the identification of P0 as an important autoantigen
in CIDP may suggest the development of Ag-based
therapies, such as Ag-specific DNA vaccination or
infusion of Ag-coupled cells;
4) the demonstration of the altered B cell phenotype in
APECED patients may suggest the possible utility of
future anti B-cell treatments such as Rituximab in
order to control an underlying immunological
defect therefore avoid the disease progression to
multiorgan autoimmunity.
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